The mission of the Laoui group is to constantly improve our understanding of the immune compartment in tumors to develop novel cancer therapies against tumor progression, tumor relapse and metastasis. More specifically, the heterogeneity of myeloid cells, focusing in particular on tumor-derived conventional dendritic cells (cDCS), is used as a target for therapeutic intervention. Our research has enabled us to uncover the genetic, phenotypic and functional characteristics of immune cell subpopulations in different activation states in the tumor microenvironment. Indeed, pioneering research published in Nature Communications, has identified and characterized different cDC subsets in the tumor and proven their utility as novel cell-based cancer therapy. In addition, several projects are ongoing in the lab focusing on further improving cDC therapy, bringing it to the clinic as well as increasing the fundamental understanding of their activity and their relation to other cell types within the tumor microenvironment. These projects allowed to build and expand our expertise on both on in vivo orthotopic cancer models for breast cancer, lung cancer and ovarian cancer, analysis techniques such as scRNA-seq, CITE-seq, advanced flow cytometric analysis and Resolve spatial transcriptomics as well as functional ex-vivo and in vitro assays.
Cancer Cell. 2022 Nov 21:S1535-6108(22)00549-9. doi: 10.1016/j.ccell.2022.11.002. Online ahead of print.
PMID: 36423635 | DOI: 10.1016/j.ccell.2022.11.002
Cancers (Basel). 2022 Aug 21;14(16):4037. doi: 10.3390/cancers14164037.
PMID: 36011029 | PMC: PMC9406463 | DOI: 10.3390/cancers14164037
Cancer Res. 2022 Oct 17;82(20):3785-3801. doi: 10.1158/0008-5472.CAN-22-0094.
PMID: 35979635 | DOI: 10.1158/0008-5472.CAN-22-0094
Int Rev Cell Mol Biol. 2022;367:149-182. doi: 10.1016/bs.ircmb.2022.01.002. Epub 2022 Feb 28.
PMID: 35461657 | DOI: 10.1016/bs.ircmb.2022.01.002
Int J Mol Sci. 2022 Jan 14;23(2):904. doi: 10.3390/ijms23020904.
PMID: 35055096 | PMC: PMC8778019 | DOI: 10.3390/ijms23020904